FUTURE OF HEALTHCARE
Athlete | September 27, 2022
Whether for active adults or Olympians, Athlete Training and Health (ATH) encourages its athletes to strive for their own personal best. ATH is raising its own bar on community health and performance training once again, with the announcement of two new facilities in the Houston area and the addition of another world-renowned coach to its executive staff.
“What we know is that evidence-led training allows everyone to benefit from the science behind the best in health and performance. Expanding and offering this world-class environment and approach will benefit athletes of all ages and abilities. We are pleased to collaborate with healthcare systems, professional sports teams, universities and school districts to continue pursuing a new level of health and performance training for many communities.”
Greg Centilli, chief operating officer for ATH and a recent addition to the growing ATH organization
Construction has begun on a new ATH sports medicine and human performance facility in Pearland. Located on the Memorial Hermann Pearland Hospital campus at 16100 South Freeway, the roughly 13K-square-foot facility will house unparalleled human performance expertise and opportunities to train in an adult fitness space, a professional sport-style weight room, and on indoor and outdoor turf fields. The facility, a collaboration between ATH, Memorial Hermann and UT Physicians Orthopedics, is expected to open fall 2023.
Also in the works is an ATH facility in Cypress, also in collaboration with Memorial Hermann. On the campus of Memorial Hermann Cypress Hospital at 27800 Highway 290, ATH will open and operate a roughly 13K-square-foot facility in 2024. At this location, student, collegiate, professional and adult athletes will find the expertise needed to up their game on their own performance.
“We are extremely pleased to welcome Professor Cronin to ATH. His science-based expertise and educational experience, alongside his international standing, will help educate investors and the general markets on the significance and industry importance of ATH-led initiatives,” said Centilli.
Cronin serves as professor of strength and conditioning at the Sports Performance Research Institute of New Zealand (SPRINZ) at Auckland University of Technology (AUT). His research interests are in human movement, particularly around strengthening of muscle, injury resistance, return to play and high-performance sports. Cronin’s research has been published in more than 400 peer-reviewed papers.
AUT and ATH have a long-standing history. Post-graduate fellows from AUT conduct research at ATH as part of a team involving coaches and select students, as well as collaborate on sport technology development.
“I know the organization well, and my research interests and expertise align well with ATH’s interest in sporting performance and allied health, so I’m very excited to be advising ATH about the latest science-based studies and learnings to support their people, programs and products,” Cronin said.
While its clients celebrate personal victories, ATH celebrates industry wins. Readers of Living Magazine recently voted ATH the “2022 Best Health Club/Gym” winner in McKinney/Allen and in Katy/Fulshear via an annual award competition that allows readers to nominate and then vote for their favorite companies by category and market.
ATH also was honored to be named a “2022 Neighborhood Favorite” in NextDoor’s annual celebration of local businesses, and a finalist for “2022 Best Gym/Fitness Center in Houston” by readers of Houston Chronicle in an annual awards competition voted on by Houstonians.
“While it’s important for us to acknowledge the hard work of our coaches and staff who make awards like these possible, it’s our job to continuously raise the bar, so we consider this just the beginning,” noted Centilli. “We are excited about what we have accomplished and are even more excited for the developments ahead.”
Whether it’s losing the pandemic pounds, living in a healthier body, or even reaching the pinnacle of your sport, the certified, experienced sports performance experts at ATH have the expertise and a program tailored just for you.
ABOUT ATHLETE TRAINING AND HEALTH (ATH)
ATH is more than a gym. It’s a place of community, inspiration and results. ATH provides award-winning adult fitness and sports performance training for youth, collegiate and professional athletes. ATH utilizes best practices from human performance research to provide a world-class training environment for athletes and adults of all fitness levels collaborating with hospitals, professional sports teams, universities and school districts to set new standards for health and performance training. ATH invests heavily in the post-graduate education of its performance coaches, who in turn develop evidence-led training programs guaranteed to deliver sustainable results. ATH currently operates two training centers in the Houston metro area and one in Allen, north of DFW.
ASEP Medical Holdings Inc | November 25, 2022
Asep Medical Holdings Inc. is pleased to announce that, for recruitment, incentivization, and retention purposes, it has granted to certain officers and advisors an aggregate of 1,080,000 stock options to purchase up to 1,080,000 common shares of the Company of which 200,000 are exercisable at a price of $0.30 per Share until September 29, 2032, 200,000 are exercisable at a price of $0.30 per share until October 1, 2032, and 680,000 are exercisable at a price of $0.30 per share until November 24, 2032.
ABOUT ASEP MEDICAL HOLDINGS INC
Asep Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.
Sepset Biosciences Inc. is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The semester test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 1-2 hours of first clinical presentation while other diagnostics only provide diagnosis after 24-36 hours. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis.
ABT Innovations Inc.'s peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections anti-inflammatories, anti-infective immune modulators, and vaccine adjuvants.
Antengene Corporation Limited | September 19, 2022
Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, announced that ATG-101, the company's in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development and the future registration of ATG-101.
At present, no PD-L1/4-1BB bispecific antibody has been approved for the treatment of pancreatic cancer worldwide.
Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions. Orphan Drug Designations by the U.S. FDA are meant to support the development of drug candidates that could potentially bring substantial therapeutic benefits to patients with rare diseases and to provide incentives to the subsequent development, registration and commercialization to designated drugs. Those incentives include tax credit on expenditures incurred in clinical studies, a waiver of the New Drug Application (NDA) fee, and 7-year market exclusivity in the U.S. regardless of the patent status of the designated drug.
Pancreatic cancer is a highly malignant type of gastrointestinal cancer. According to the statistics by the World Health Organization (WHO), pancreatic cancer was ranked 13th and 7th globally by its incidence and mortality rates in 2012. In 2018, the U.S. reported over 55,000 newly- diagnosed pancreatic cancer cases and 44,330 related deaths. Whereas still defined as an orphan disease currently, it is projected that by 2030, pancreatic cancer will become the second most common cause of cancer-related deaths.
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 demonstrated significant anti-tumor activity in animal models of resistant tumors as well as those that had progressed on anti-PD-1/L1 treatment. Furthermore, ATG-101 has also shown an excellent safety profile in Good Laboratory Practice (GLP) toxicology studies. ATG-101 is the first PD-L1/4-1BB bispecific antibody entering clinical development in Australia and is currently being evaluated in clinical studies in Australia, China, and the U.S.
"We are very encouraged by this Orphan Drug Designation from the U.S. FDA and are hopeful that ATG-101 will offer a novel therapeutic to patients with pancreatic cancer. As Antengene's first in-house developed asset with global rights, ATG-101 has already entered clinical development in Australia, China, and the U.S. We will strive to accelerate the global clinical development of ATG-101 in efforts to provide a new treatment option to patients around the world."
Dr. Bo Shan, Antengene's Chief Scientific Officer
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".
Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® already approved in mainland China, South Korea, Singapore and Australia.
FUTURE OF HEALTHCARE
Tebra | November 22, 2022
Tebra, a leader in practice growth technology and cloud-based clinical and financial software, announced that its Chief Technology Officer Kyle Ryan was named in the Healthcare Technology Report’s list of Top 25 Healthcare Technology CTOs of 2022. The annual list recognizes the most accomplished executives in healthcare technology who are leading teams in delivering cutting edge products that boost operations and improve efficiency for their customers.
The CTOs on this year’s list have a wide range of impressive backgrounds, but each is the driving force behind their company’s technology innovations, ensuring software functionality and effectiveness. Read the full report here.
“Kyle has been an integral part of the executive leadership team at Tebra and has built a strong partnership between product management and the technology team within the organization. He has vast knowledge about healthcare IT and how it applies to solving business problems and is keenly customer focused and is always taking time to understand customer needs at a deeper level. Kyle’s an outstanding ambassador for the company and prides himself on developing a healthy and high-performance culture.”
Dan Rodrigues, CEO of Tebra
Kyle is responsible for all areas of technology with a focus on the vision and strategy for Tebra’s suite of products and services. He believes that great products are created through a keen customer focus, groundbreaking ideas, precise engineering, and efficient execution.
“I am honored to be included in this list of prestigious technology leaders,” Kyle said. “This recognition also highlights the technology team’s passion for improving healthcare and the company’s mission of providing independent practices with digital tools and support to thrive in a new era of healthcare.”
In 2021, with a combined mission to unlock better healthcare, Kareo and PatientPop joined forces to form Tebra — the operating system for the connected practice of the future. With an all-in-one, purpose-built platform to drive practice success and modernize every step of the patient journey, Tebra provides digital tools and support to attract new patients, deliver modern care, get paid quickly, and operate efficiently.